A client presents for a follow-up visit. The patient has been taking atorvastatin for treatment of dyslipidemia for about 1 year. The patients lipid panel is notable for triglyceride level of 600 mg/dL. Which additional medication does the nurse anticipate will be prescribed for this client

Introduction: Hypertriglyceridemia, defined here by levels exceeding 500 mg/dL, significantly increases the risk of acute pancreatitis and cardiovascular events. When statin therapy alone is insufficient to manage triglycerides, clinicians often add fibrates to activate peroxisome proliferator-activated receptors (PPAR-alpha), which enhances the clearance of triglyceride-rich lipoproteins. A. Prescribing a second statin drug is not a standard clinical practice and significantly increases the risk of adverse effects such as myopathy and rhabdomyolysis without providing a synergistic benefit. Statins primarily target LDL cholesterol rather than providing the intensive triglyceride reduction required for a level of 600 mg/dL. B. Niacin, or Vitamin B3, can lower triglycerides and raise HDL levels, but its use has declined due to significant side effects like intense flushing and potential hepatotoxicity. While it is an option, it is generally considered less effective and less tolerated than fibrates for isolated, severe hypertriglyceridemia. C. Fenofibrate is the drug of choice for treating severe hypertriglyceridemia because it effectively lowers triglyceride levels by up to 50 percent. It works by stimulating lipoprotein lipase activity and decreasing the hepatic synthesis of VLDL, making it the most appropriate anticipated addition for a patient with triglycerides at 600 mg/dL. D. Cholestyramine is a bile acid sequestrant that primarily works to lower LDL cholesterol by binding bile acids in the gastrointestinal tract. However, bile acid sequestrants can actually cause a paradoxical increase in triglyceride levels, making this medication contraindicated for a patient who already has severely elevated triglycerides.